Neurophysiology Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Perspective - Neurophysiology Research (2023) Volume 5, Issue 4

Understanding ocular myasthenia gravis: A window into rare neuromuscular disorder

Catherine Skarf *

Department of Ophthalmology, University of Liege, Liege, Belgium.

*Corresponding Author:
Catherine Skarf
Department of Ophthalmology,
University of Liege
Liege, Belgium

Received:10-Jul-2023, Manuscript No. AANR-23-110613;Editor assigned: 12-Jul-2023, PreQC No. AANR-23-110613(PQ);Reviewed:26-Jul-2023, QC No. AANR-23-110613;Revised:28-Jul-2023, Manuscript No. AANR-23-110613 (R); Published:04-Aug-2023, DOI: 10.35841/ aanr-5.4.158

Citation: Catherine Skarf. Understanding ocular myasthenia gravis: A window into rare neuromuscular disorder. Neurophysiol Res. 2023; 5(4):158

Visit for more related articles at Neurophysiology Research


In the realm of neuromuscular disorders, one condition that stands out due to its unique presentation and impact is Ocular Myasthenia Gravis (OMG). This relatively rare autoimmune disorder affects the muscles responsible for controlling eye movement, resulting in a variety of ocular symptoms. Though less common than its generalized counterpart, ocular myasthenia gravis provides valuable insights into the complexities of autoimmune disorders and sheds light on the challenges of diagnosis and management.

Ocular myasthenia gravis:

Myasthenia Gravis (MG) is an autoimmune disorder that targets the neuromuscular junction – the point where nerve signals meet muscle contractions. This results in muscle weakness and fatigue, which can vary in intensity depending on the form of the disease. Ocular Myasthenia Gravis specifically focuses its effects on the muscles that control eye movement. While the symptoms in this form of MG are localized to the eyes, they can still significantly impact an individual's quality of life [1].


The hallmark of ocular myasthenia gravis is fluctuating muscle weakness that primarily affects the eye muscles. Common symptoms include:

Ptosis: Drooping of the upper eyelid due to weakness in the levator palpebrae superioris muscle.

Diplopia: Double vision, which arises when the weakened eye muscles are unable to synchronize properly, causing two different images to be perceived.

Ophthalmoplegia: Limited eye movement, leading to difficulty in moving the eyes in certain directions.

Blurred vision: Weakened eye muscles can result in difficulty focusing and maintaining clear vision.

These symptoms often present in a variable manner – they may worsen with sustained use of the affected muscles and improve after rest [2].

Symptoms and Diagnosis:

Diagnosing ocular myasthenia gravis can be challenging due to the fluctuating nature of symptoms and their potential resemblance to other eye conditions. A thorough medical history, clinical examination and certain specialized tests can aid in the diagnosis:

Tensilon test: An injection of a medication called edrophonium (Tensilon) can provide temporary relief from muscle weakness if the individual has myasthenia gravis.

Ice pack test: Applying a cold pack to the affected eye can temporarily improve ptosis, confirming the diagnosis.

Electromyography (EMG): This test measures the electrical activity of muscles, helping to identify abnormal patterns characteristic of myasthenia gravis.

Blood tests: Measuring the levels of antibodies, such as anti-acetylcholine receptor antibodies, can help support the diagnosis [3].

Management and Treatment:

While ocular myasthenia gravis tends to be less severe than the generalized form, it still requires careful management to alleviate symptoms and enhance the patient's quality of life.

Medications: Acetylcholinesterase inhibitors, such as pyridostigmine, can help improve neuromuscular transmission and alleviate symptoms.

Immunosuppressive therapy: In cases of more severe symptoms, immunosuppressive drugs like corticosteroids, azathioprine, or mycophenolate mofetil might be prescribed to suppress the autoimmune response.

Thymectomy: If the individual has an enlarged thymus (a gland involved in immune system development), surgical removal might be considered.

Supportive measures: Strategies like wearing an eye patch to manage diplopia or using prisms in eyeglasses to correct double vision can be helpful.

Living with ocular myasthenia gravis:

Living with ocular myasthenia gravis requires individuals to be proactive in managing their condition. Regular communication with healthcare providers, adhering to medication regimens and adopting stress-reduction techniques can aid in maintaining a good quality of life. It's important to be aware of potential triggers that can exacerbate symptoms, such as illness, fatigue, stress, or certain medications [4].


Ocular Myasthenia Gravis shines a light on the intricate relationship between the immune system and neuromuscular function. While it’s localized impact on the eyes may make it less debilitating than generalized MG, its effects on vision and overall well-being should not be underestimated. Early diagnosis, appropriate treatment and patient education play crucial roles in managing this condition effectively. Ongoing research in autoimmune disorders, like ocular myasthenia gravis, not only improves our understanding of complex medical phenomena but also enhances our ability to provide targeted care to those affected by these conditions.


  1. Sommer N, Sigg B, Melms A, et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J Neurol Neurosurg Psychiatry. 1997;62(2):156-62.
  2. Indexed at, Google Scholar, Cross Ref

  3. Vaphiades MS, Bhatti MT, Lesser RL. Ocular myasthenia gravis. Curr Opin Ophthalmol. 2012;23(6):537-42.
  4. Indexed at, Google Scholar, Cross Ref

  5. Kupersmith MJ, Ying G. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment. Br J Ophthalmol. 2005;89(10):1330-4.
  6. Indexed at, Google Scholar, Cross Ref

  7. Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology. 2008;71(17):1335-41.
  8. Indexed at, Google Scholar, Cross Ref

  9. Jayam Trouth A, Dabi A, Solieman N, et al. Myasthenia gravis: a review. Autoimmune Dis. 2012;2012.
  10. Indexed at, Google Scholar, Cross Ref

Get the App